<DOC>
	<DOC>NCT01191801</DOC>
	<brief_summary>This study will compare the overall survival (OS) between treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.</brief_summary>
	<brief_title>Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description>Other objectives of this study include comparing the following between treatment groups: Complete remission (CR) rate Safety and tolerability Combined CR rate, defined as CR+CRp+CRi Overall remission (OR) rate Event-free survival (EFS) Durability of remission (CR and combined CR) assessed by leukemia-free survival (LFS) Percentage of patients who have post-treatment transplantation</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Provide signed, written informed consent Are at least 18 years of age Have a diagnosis of AML according to World Health Organization (WHO) classification First relapsed or refractory AML (refractory to initial induction therapy) Have an ECOG score of 02 Have adequate liver and renal function as indicated by certain laboratory values Are nonfertile or agree to use an adequate method of contraception until 30 days after the last treatment Have received more than 2 cycles of induction therapy for AML Refractory to or relapsed within the previous 3 months after therapy with an IDAC or HIDACcontaining regimen Have received a hematopoietic stem cell transplant (HSCT) within the previous 3 months Have received active immunosuppressive therapy for graftversushost disease (GVHD) within 2 weeks before study start Have any other severe concurrent disease, or have a history of serious disease involving the heart, kidney, liver, or other organ system Have evidence of central nervous system involvement of active AML Have other active malignancies (including other hematologic malignancies) or been diagnosed with other malignancies within the last 12 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia Have an active, uncontrolled infection Are receiving any other investigational therapy Have received previous treatment with vosaroxin Are pregnant or lactating Have any other medical, psychological, or social condition that may interfere with consent, study participation, or followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Hematologic</keyword>
	<keyword>Hematologic diseases</keyword>
	<keyword>Blood</keyword>
	<keyword>Cancer</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Vosaroxin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>First Relapsed AML</keyword>
	<keyword>Refractory AML</keyword>
	<keyword>VALOR</keyword>
	<keyword>Sunesis</keyword>
	<keyword>Voreloxin</keyword>
	<keyword>SNS-595</keyword>
</DOC>